Successful treatment of gastric ulcer with proglumide (Milid) in outpatients (double blind trial).

Eleven male and five woman gastric ulcer outpatients as well as twenty eight male and seven woman duodenal ulcer outpatients received Proglumide (1200 mg/day) or magnesiumtrisilicate (1320 mg/day) in a prospective double window blind study. The sizes of the ulcers were evaluated by endoscopy before and after 4 weeks treatment. A complete healing of gastric ulcers was seen in 75% (n sama dengan 8) of the patients acquiring Proglumide and 25% (n = 8) of the antacid treated regulates (p lower than 0. 05; x2 test). The cured area was significantly (p less than 0. 05) larger in the Proglumide 91 mm2) as compared to the anticida group (23 mm2). In addition, the fifty percent time of the ulcer-healing was significantly (p less than 0. 05) shorter in the Proglumide treated patients (18 days and 26 days respectively). Right now there was no significant result of the drug on the duodenal ulcers. Typically the spontaneous healing rate was 61% in the antacid (n = 18) and 59% in the Proglumide treated (n = 17) patients. The drug will not effect the basal and pentagastrin stimulated digestive, gastrointestinal secretion nor the serum gastrin concentration. No part effects on stress, blood vessels cell count, transaminases or blood glucose concentrations could be observed.